Biosimilars: Global Markets
Description
Report Scope
This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.
For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.
The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization’s business segments, financials, product portfolios and recent developments.
Report Includes
142 data tables and 74 additional tables
An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region
Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors
Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product
Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
An analysis of key patent publications, grants and applications in biosimilars
Analysis of the competitive landscape featuring companies’ market shares, strategic alliances, M&A activity and a venture funding outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies
Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Companies Mentioned
ACCORD BIOPHARMA INC.
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
BIOCON BIOLOGICS LTD.
BIOGEN
CELLTRION INC.
COHERUS BIOSCIENCES
FRESENIUS KABI AG
LILLY
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.
This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.
For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.
The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization’s business segments, financials, product portfolios and recent developments.
Report Includes
142 data tables and 74 additional tables
An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region
Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors
Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product
Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
An analysis of key patent publications, grants and applications in biosimilars
Analysis of the competitive landscape featuring companies’ market shares, strategic alliances, M&A activity and a venture funding outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies
Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Companies Mentioned
ACCORD BIOPHARMA INC.
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
BIOCON BIOLOGICS LTD.
BIOGEN
CELLTRION INC.
COHERUS BIOSCIENCES
FRESENIUS KABI AG
LILLY
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.
Table of Contents
219 Pages
- Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Insights
- Chapter 2 Market Overview
- Introduction
- Terminology of Biosimilars
- Key Terms in Biosimilars
- WHO Guidelines on Evaluation of Biosimilars
- Pharmacovigilance/Post-Approval Monitoring
- Biosimilars Vs. Biobetters
- Popular Types of Biosimilars
- Recombinant Hormones
- Recombinant Growth Factors
- Monoclonal Antibodies (mAbs)
- Fusion Proteins
- Interferons
- Low Molecular Weight Heparins (LMWHs)
- Chapter 3 Market Dynamics
- Introduction
- Market Drivers
- Patent Expirations of Major Biologics
- Cost-effectiveness and Healthcare Savings
- Market Restraints
- Intellectual Property and Legal Issues
- Manufacturing and Supply Chain Complexities
- Market Opportunities
- Increasing Access, Adoption and Awareness
- Emerging Markets
- Chapter 4 Emerging Technologies
- Advanced Analytical Techniques
- Single-use Bioreactors
- Cell Line Engineering and Expression Systems
- Chapter 5 Market Segmentation Analysis
- Segmentation Breakdown
- Global Biosimilars Market, by Product Type
- Monoclonal Antibodies
- Recombinant Growth Factors
- Recombinant Hormones
- Fusion Protein
- Others
- Global Biosimilars Market, by Therapeutic Application
- Cancer and Related Disorders
- Autoimmune and Inflammatory Diseases
- Diabetes
- Anemia
- Growth Hormone Deficiency
- Other Diseases
- Geographic Breakdown
- Global Biosimilars Market, by Region
- Market Size and Forecast
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
- Chapter 6 Competitive Landscape and Patent Analysis
- Overview
- Key Market Leaders
- Emerging Players
- Strategic Analysis
- Challenges and Future Trends
- Patent Analysis
- Patent Regulations in Favor of Branded Biologics
- Market Exclusivity
- Chapter 7 Regulatory Aspects
- Overview
- Biosimilar Regulations in Europe
- Biosimilar Regulations in the U.S.
- Principle of Exclusivity
- Biosimilar Regulations in China
- Chapter 8 Sustainability in the Global Biosimilars Market: An ESG Perspective
- Introduction to ESG
- ESG Performance in the Market
- ESG Practices in the Biosimilars Industry
- Environmental Performance
- Concluding Remarks from BCC Research
- Chapter 9 Appendix
- Research Methodology
- Sources
- Abbreviations
- Company Profiles
- ACCORD BIOPHARMA INC.
- ALVOTECH
- AMGEN INC.
- AMNEAL PHARMACEUTICALS LLC.
- BIOCON BIOLOGICS LTD.
- BIOGEN
- CELLTRION INC.
- COHERUS BIOSCIENCES
- FRESENIUS KABI AG
- LILLY
- PFIZER INC.
- SAMSUNG BIOEPIS
- SANDOZ GROUP AG
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- VIATRIS INC.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
